Dataset Information

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.

ABSTRACT: Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum antitumor strategy, the populations eligible for cancer immunotherapy are rapidly expanding. However, the clinical applications of ICIs in cancer patient populations with special issues, a term that refers to complex subgroups of patients with comorbidities, special clinical conditions, or concomitant medications who are routinely excluded from prospective clinical trials of ICIs or are underrepresented in these trials, represent a great real-world challenge. Although the Chinese Society of Clinical Oncology (CSCO) has provided recommendations for screening before the use of ICIs in special populations, the recommendations for full-course management remain insufficient. The CSCO Expert Committee on Immunotherapy organized leading medical oncology and multidisciplinary experts to develop a consensus that will serve as an important reference for clinicians to guide the proper application of ICIs in special patient populations. This article is a translation of a study first published in Chinese in The Chinese Clinical Oncology (ISSN 1009-0460, CN 32-1577/R) in May 2022 (27(5):442-454). The publisher of the original paper has provided written confirmation of permission to publish this translation in Therapeutic Advances in Medical Oncology.

SUBMITTER: Wang J

PROVIDER: S-EPMC10357053 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.

Wang Jun J Zhang Bicheng B Peng Ling L Liu Xiufeng X Sun Jianguo J Su Chunxia C Wang Huijuan H Zhao Zheng Z Si Lu L Duan Jianchun J Zhang Hongmei H Li Mengxia M Zhu Bo B Zhang Li L Li Jin J Guo Jun J Luo Rongcheng R Qiu Wensheng W Ye Dingwei D Chu Qian Q Cui Jiuwei J Dong Xiaorong X Fan Yun Y Gao Quanli Q Guo Ye Y He Zhiyong Z Li Wenfeng W Lin Gen G Liu Lian L Liu Yutao Y Qin Haifeng H Ren Shengxiang S Ren Xiubao X Wang Yongsheng Y Xue Junli J Yang Yunpeng Y Yang Zhenzhou Z Yue Lu L Zhan Xianbao X Zhang Junping J Ma Jun J Qin Shukui S Wang Baocheng B

Therapeutic advances in medical oncology 20230716

Immune checkpoint inhibitors (ICIs) targeting programmed cell death 1, programmed cell death ligand 1, and cytotoxic T lymphocyte-associated antigen-4 have shown significantly durable clinical benefits and tolerable toxicities and have improved the survival of patients with various types of cancer. Since 2018, the National Medical Products Administration of China has approved 17 ICIs as the standard treatment for certain advanced or metastatic solid tumors. As ICIs represent a broad-spectrum ant ...[more]

PMID: 37484525

Similar Datasets

Project description:BackgroundFamilial dysautonomia (Riley-Day syndrome, hereditary sensory autonomic neuropathy type-III) is a rare genetic disease caused by impaired development of sensory and afferent autonomic nerves. As a consequence, patients develop neurogenic dysphagia with frequent aspiration, chronic lung disease, and chemoreflex failure leading to severe sleep disordered breathing. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of respiratory disorders in familial dysautonomia.MethodsWe performed a systematic review to summarize the evidence related to our questions. When evidence was not sufficient, we used data from the New York University Familial Dysautonomia Patient Registry, a database containing ongoing prospective comprehensive clinical data from 670 cases. The evidence was summarized and discussed by a multidisciplinary panel of experts. Evidence-based and expert recommendations were then formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system.ResultsRecommendations were formulated for or against specific diagnostic tests and clinical interventions. Diagnostic tests reviewed included radiological evaluation, dysphagia evaluation, gastroesophageal evaluation, bronchoscopy and bronchoalveolar lavage, pulmonary function tests, laryngoscopy and polysomnography. Clinical interventions and therapies reviewed included prevention and management of aspiration, airway mucus clearance and chest physical therapy, viral respiratory infections, precautions during high altitude or air-flight travel, non-invasive ventilation during sleep, antibiotic therapy, steroid therapy, oxygen therapy, gastrostomy tube placement, Nissen fundoplication surgery, scoliosis surgery, tracheostomy and lung lobectomy.ConclusionsExpert recommendations for the diagnosis and management of respiratory disease in patients with familial dysautonomia are provided. Frequent reassessment and updating will be needed.

Dataset Information

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.

Publications

Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets